Atara Biotherapeutics Inc
NASDAQ:ATRA
Balance Sheet
Balance Sheet Decomposition
Atara Biotherapeutics Inc
Current Assets | 101.9m |
Cash & Short-Term Investments | 51.7m |
Receivables | 34.1m |
Other Current Assets | 16m |
Non-Current Assets | 63.6m |
PP&E | 58.8m |
Other Non-Current Assets | 4.8m |
Current Liabilities | 142.2m |
Accounts Payable | 3.7m |
Accrued Liabilities | 59.8m |
Other Current Liabilities | 78.7m |
Non-Current Liabilities | 122.5m |
Long-Term Debt | 34.7m |
Other Non-Current Liabilities | 87.9m |
Balance Sheet
Atara Biotherapeutics Inc
Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Cash & Cash Equivalents |
22
|
24
|
48
|
79
|
61
|
74
|
200
|
106
|
93
|
26
|
|
Cash Equivalents |
22
|
24
|
48
|
79
|
61
|
74
|
200
|
106
|
93
|
26
|
|
Short-Term Investments |
82
|
297
|
208
|
87
|
249
|
185
|
300
|
265
|
150
|
26
|
|
Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
40
|
34
|
|
Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
40
|
34
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
10
|
|
Other Current Assets |
2
|
4
|
5
|
6
|
12
|
14
|
21
|
13
|
10
|
6
|
|
Total Current Assets |
106
|
325
|
261
|
172
|
322
|
273
|
523
|
385
|
295
|
102
|
|
PP&E Net |
0
|
0
|
3
|
44
|
69
|
68
|
63
|
80
|
74
|
59
|
|
PP&E Gross |
0
|
0
|
3
|
44
|
69
|
68
|
63
|
80
|
74
|
59
|
|
Accumulated Depreciation |
0
|
0
|
0
|
1
|
5
|
12
|
20
|
29
|
12
|
16
|
|
Other Long-Term Assets |
0
|
0
|
0
|
2
|
2
|
2
|
2
|
4
|
7
|
5
|
|
Total Assets |
106
N/A
|
325
+206%
|
264
-19%
|
218
-17%
|
392
+80%
|
343
-12%
|
588
+72%
|
468
-20%
|
376
-20%
|
166
-56%
|
|
Liabilities | |||||||||||
Accounts Payable |
0
|
1
|
3
|
15
|
4
|
8
|
7
|
17
|
7
|
4
|
|
Accrued Liabilities |
1
|
8
|
6
|
10
|
30
|
29
|
42
|
48
|
63
|
60
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
Other Current Liabilities |
1
|
1
|
1
|
3
|
6
|
0
|
34
|
41
|
8
|
78
|
|
Total Current Liabilities |
3
|
10
|
10
|
28
|
40
|
37
|
83
|
106
|
79
|
142
|
|
Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
35
|
|
Other Liabilities |
0
|
0
|
1
|
12
|
13
|
15
|
43
|
83
|
167
|
88
|
|
Total Liabilities |
3
N/A
|
10
+241%
|
10
+3%
|
40
+291%
|
53
+33%
|
52
-2%
|
126
+141%
|
189
+50%
|
250
+33%
|
265
+6%
|
|
Equity | |||||||||||
Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Retained Earnings |
41
|
98
|
177
|
297
|
527
|
818
|
1 125
|
1 465
|
1 693
|
1 969
|
|
Additional Paid In Capital |
144
|
414
|
431
|
475
|
867
|
1 109
|
1 587
|
1 745
|
1 822
|
1 870
|
|
Other Equity |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
|
Total Equity |
103
N/A
|
315
+205%
|
254
-19%
|
178
-30%
|
339
+91%
|
291
-14%
|
462
+59%
|
280
-40%
|
127
-55%
|
99
N/A
|
|
Total Liabilities & Equity |
106
N/A
|
325
+206%
|
264
-19%
|
218
-17%
|
392
+80%
|
343
-12%
|
588
+72%
|
468
-20%
|
376
-20%
|
166
-56%
|
|
Shares Outstanding | |||||||||||
Common Shares Outstanding |
20
|
29
|
29
|
31
|
46
|
57
|
83
|
92
|
96
|
106
|